United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages

United Therapeutics Co. (NASDAQ:UTHR) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $350.36.

Several research analysts have recently commented on UTHR shares. Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Oppenheimer boosted their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $310.00 to $321.00 in a research report on Thursday, July 11th.

United Therapeutics Price Performance

Shares of UTHR stock opened at $353.00 on Friday. United Therapeutics has a twelve month low of $208.62 and a twelve month high of $366.08. The stock has a market capitalization of $15.70 billion, a price-to-earnings ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The stock has a fifty day simple moving average of $338.55 and a two-hundred day simple moving average of $290.39. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm posted $5.24 earnings per share. On average, analysts predict that United Therapeutics will post 24.86 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the sale, the director now owns 1,750 shares in the company, valued at approximately $569,362.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $41,076.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the completion of the sale, the director now owns 1,750 shares in the company, valued at approximately $569,362.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 110,922 shares of company stock worth $36,541,398. 12.50% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Hedge funds have recently modified their holdings of the stock. Meiji Yasuda Asset Management Co Ltd. boosted its position in United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares in the last quarter. Toronto Dominion Bank boosted its position in United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares in the last quarter. ClariVest Asset Management LLC boosted its position in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares in the last quarter. Finally, Access Investment Management LLC boosted its position in United Therapeutics by 0.8% during the second quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock worth $2,314,000 after purchasing an additional 55 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.